tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

EYPT Stock Latest News

EyePoint price target lowered to $26 from $30 at Mizuho
The FlyEyePoint price target lowered to $26 from $30 at Mizuho
3d ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
3d ago
EYPT
Positive Buy Rating for EyePoint Pharmaceuticals Driven by Clinical Progress and Strong Financial Position
PremiumRatings
Positive Buy Rating for EyePoint Pharmaceuticals Driven by Clinical Progress and Strong Financial Position
4d ago
EYPT
EyePoint Pharma’s Promising Q1 2025 Financial Results
PremiumCompany Announcements
EyePoint Pharma’s Promising Q1 2025 Financial Results
11d ago
EYPT
EyePoint Pharma’s Earnings Call Highlights Positive Momentum
PremiumCompany Announcements
EyePoint Pharma’s Earnings Call Highlights Positive Momentum
11d ago
EYPT
EyePoint Pharmaceuticals: Strong Buy Rating Backed by Promising Clinical Trial Progress and Market Potential
PremiumRatingsEyePoint Pharmaceuticals: Strong Buy Rating Backed by Promising Clinical Trial Progress and Market Potential
12d ago
EYPT
EyePoint Pharmaceuticals Reports Q1 2025 Financial Results
Premium
Company Announcements
EyePoint Pharmaceuticals Reports Q1 2025 Financial Results
12d ago
8K
EYPT
EyePoint reports Q1 EPS (65c), consensus (69c)
Premium
The Fly
EyePoint reports Q1 EPS (65c), consensus (69c)
12d ago
EYPT
EyePoint sees cash runway into 2027
PremiumThe Fly
EyePoint sees cash runway into 2027
12d ago
EYPT
Is EYPT a Buy, Before Earnings?
PremiumPre-Earnings
Is EYPT a Buy, Before Earnings?
21d ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
1M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
2M ago
EYPT
EyePoint Pharma’s Earnings Call: Clinical Progress Amid Financial Challenges
PremiumCompany AnnouncementsEyePoint Pharma’s Earnings Call: Clinical Progress Amid Financial Challenges
2M ago
EYPT
EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating
Premium
Ratings
EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating
2M ago
EYPT
EyePoint Pharmaceuticals Reports 2024 Financial Results
Premium
Company Announcements
EyePoint Pharmaceuticals Reports 2024 Financial Results
2M ago
EYPT
EyePoint reports Q4 EPS (64c), consensus (48c)
PremiumThe Fly
EyePoint reports Q4 EPS (64c), consensus (48c)
2M ago
EYPT
EyePoint expects cash to fund operations into 2027
PremiumThe Fly
EyePoint expects cash to fund operations into 2027
2M ago
EYPT
Eyepoint Pharma (EYPT) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Eyepoint Pharma (EYPT) Q4 Earnings Cheat Sheet
3M ago
EYPT
EyePoint Pharmaceuticals: Buy Rating Backed by Promising Duravyu Phase 2 Results and Growth Potential in Undervalued Market
PremiumRatings
EyePoint Pharmaceuticals: Buy Rating Backed by Promising Duravyu Phase 2 Results and Growth Potential in Undervalued Market
3M ago
EYPT
EyePoint Pharmaceuticals: An Undervalued Opportunity Amid Market Overreaction and Financing Concerns
PremiumRatingsEyePoint Pharmaceuticals: An Undervalued Opportunity Amid Market Overreaction and Financing Concerns
3M ago
EYPT
Collegium appoints Nancy Lurker to board of directors
Premium
The Fly
Collegium appoints Nancy Lurker to board of directors
3M ago
COLL
EYPT
EyePoint announces Phase 2 VERONA trial met primary endpoint
Premium
The Fly
EyePoint announces Phase 2 VERONA trial met primary endpoint
3M ago
EYPT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >